Protalix BioTherapeutics To Present Data From Phase I Clinical Trial Of PRX-115 Recombinant PEGylated Uricase Product Candidate
Protalix BioTherapeutics To Present Data From Phase I Clinical Trial Of PRX-115 Recombinant PEGylated Uricase Product Candidate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.